Recombinant Human 4-1BB/TNFRSF9/CD137 Protein

Name: Recombinant Human 4-1BB/TNFRSF9/CD137 Protein
Brand: Novus Biologicals
SKU: NBP2-34958

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-34958

Submit a review

Product Datasheet / COA

Catalog #

Availability

Size / Price

Qty

100% Guarantee

Product Specifications
Scientific Data
Preparation & Storage
Background
Product Documents
Specific Notices

Key Product Details

Source

E. coli

Accession #

Q07011

Conjugate

Unconjugated

Applications

Bioactivity, SDS-PAGE

View all 4-1BB/TNFRSF9/CD137 Proteins and Enzymes »

Product Specifications

Description

A single non-glycosylated polypeptide chain containing 166 amino acids corresponding to 4-1BB/TNFRSF9/CD137 Source: E. coli

Uniprot ID: Q07011

Amino Acid Sequence: ERTRSLQDPC SNCPAGTFCD NNRNQICSPC PPNSFSSAGG QRTCDICRQC KGVFRTRKEC SSTSNAECDC TPGFHCLGAG CSMCEQDCKQ GQELTKKGCK DCCFGTFNDQ KRGICRPWTN CSLDGKSVLV NGTKERDVVC GPSPADLSPG ASSVTPPAPA REPGHS

This lyophilized preparation is stable for 12 months from date of receipt at -20 to -70 degrees C, preferably desiccated. Upon reconstitution, the preparation can be stored for 1 month at 2-8 degrees C under sterile conditions, and for 3 months at -20 degrees C to -70 degrees C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Stock solutions should be aliquoted and stored at < -20 degrees C. Further dilutions should be made in appropriate buffered solutions

Purity

> 97 % pure by SDS-PAGE and HPLC

Endotoxin Level

Less than 1 EU/ug of 4-1BB/TNFRSF9/CD137 as determined by LAL method.

Predicted Molecular Mass

17.7 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Activity

CD137 protein is fully biologically active when compared to standard. The biological activity is determined by its inhibitory effect of IL-8 production using human peripheral blood mononuclear cells. About 90 % of inibition was seen using a concentration of 1 ug for both 4-1BB Ligand and 4-1BB Receptor.

Protein / Peptide Type

Recombinant Protein

Scientific Data Images for Recombinant Human 4-1BB/TNFRSF9/CD137 Protein

SDS-PAGE: Recombinant Human 4-1BB/TNFRSF9/CD137 Protein [NBP2-34958]

SDS-Page: Human 4-1BB/TNFRSF9/CD137 Protein [NBP2-34958]

Formulation, Preparation and Storage

NBP2-34958

Formulation	Lyophilized from a 0.2 um filtered concentrated solution in 10 mM PB, pH 8.0, 150 mM NaCl.
Preservative	No Preservative
Concentration	Lyoph
Reconstitution	Recommended to centrifuge prior to opening. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/mL. Apportion stock solutions into working aliquots and store at <-20C.
Format	Carrier-Free
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Store at -20 to -70C as supplied. After reconstitution, store at 2 to 8C for 1 month and at -20 to -70C for long term storage. Avoid repeated freeze-thaw cycles.

Background: 4-1BB/TNFRSF9/CD137

4-1BB, also called CD137 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9), is a type I surface glycoprotein expressed on activated T cell and natural killer (NK) cells (1,2). Human 4-1BB protein is 255 amino acids (aa) in length with a theoretical molecular weight of 28 kDa. It contains an extracellular domain, a helical transmembrane domain, and a cytoplasmic/intracellular domain (3). 4-1BB/TNFRSF9/CD137 is a costimulatory receptor that binds the ligand 4-1BBL/CD137L which is primarily expressed on antigen presenting cells (APCs) such as dendritic cells (DCs), macrophages, and B cells (1,2,4,5). The 4-1BB receptor-ligand interaction results in recruitment of TNFR-associated factor (TRAF) family adaptor proteins to 4-1BB's cytoplasmic domain (1,2,4,5). TRAF1, TRAF2, and TRAF3 are found in various homodimer and/or heterodimer configurations. Their recruitment to 4-1BB/CD137 initiates signalosome formation as well as activation of the nuclear factor-kappa B (NF-kappaB) and mitogen-activated protein kinase (MAPK) signaling cascade (1,4,5). 4-1BB/TNFRSF9/CD137 stimulation leads to increased cellular cytotoxic activity and pro-inflammatory cytokine production (1,2,4). Given its role in immune cell activation, 4-1BB has become a promising target for cancer immunotherapy (1,2,4). Current approaches to target 4-1BB include agonistic monoclonal and bispecific anti-4-1BB antibodies and well as utilizing the cytoplasmic domain of 4-1BB in generating chimeric antigen receptors (CARs) (1,2,4). 4-1BB agonists in clinical trials include Urelumab and Utolimumab. Utolimumab also has ligand blocking properties whereas Urelumab does not (1,2,4). Anti-4-1BB monoclonal antibodies are being tested as monotherapy as well as combination therapy with either other immunostimulatory monoclonal antibodies or with checkpoint blockade antibodies like anti-PD-1 (1,2,4).

References

1. Etxeberria, I., Glez-Vaz, J., Teijeira, A., & Melero, I. (2020). New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO open, 4(Suppl 3), e000733. https://doi.org/10.1136/esmoopen-2020-000733

2. Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018). Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 131(1), 49-57. https://doi.org/10.1182/blood-2017-06-741041

3. Uniport (Q07011)

4. Chester, C., Ambulkar, S., & Kohrt, H. E. (2016). 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunology, Immunotherapy: CII, 65(10), 1243-1248. https://doi.org/10.1007/s00262-016-1829-2

5. Zapata, J. M., Perez-Chacon, G., Carr-Baena, P., Martinez-Forero, I., Azpilikueta, A., Otano, I., & Melero, I. (2018). CD137 (4-1BB) signalosome: complexity is a matter of TRAFs. Frontiers in Immunology, 9, 2618. https://doi.org/10.3389/fimmu.2018.02618

Alternate Names

41BB, CD137, ILA, TNFRSF9

Gene Symbol

TNFRSF9

UniProt